Work

Major Adverse Cardiovascular Events (MACE) in Patients Randomly Assigned to Vadadustat vs. Darbepoetin Alfa during the 3 Months after Dialysis Initiation

Year: 2024

Type: article

Source: Journal of the American Society of Nephrology

DOI: 10.1681/asn.20247k5vka38

Authors: Wolfgang C. Winkelmayer, Steven K. Burke, Glenn M. Chertow, Kai-Uwe Eckardt, Eldrin F. Lewis, Wenli Luo, Todd Eric Minga, Mark J. Sarnak

Institutions: Baylor College of Medicine, Akebia Therapeutics (United States), Stanford Medicine, Stanford University, Charité – Universitätsmedizin Berlin, Tufts University

Language: English

Topic: Erythropoietin and Anemia Treatment

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4403832003

FWCI:

Cites:

Cited by:

Related to: 10